Minoxidil, finasteride, and RU58841 promote hair growth by different mechanisms, with minoxidil and prostaglandin E1 being specifically mentioned. Corticosteroids can also cause hair growth.
The conversation discusses the mechanism of action of alfatradiol (17 alpha estradiol) in treating hair loss. It explores theories that it either inhibits 5 alpha reductase to prevent T->DHT conversion or aromatizes scalp T into 17-alpha-estradiol to save hair.
Pyrilitamide (KX-826) did not show significant improvement in hair count compared to placebo after 6 months. It's unclear if it can maintain hair at baseline.
Finasteride may cause mild blood pressure-related side effects in less than 10% of users, unlike minoxidil, which has stronger effects. Alternatives like topical ketoconazole and dermarollers are suggested for those concerned about finasteride's side effects.
The conversation discusses hair loss treatments beyond the commonly known three, focusing on separating effective treatments from myths. Dutasteride and low-dose oral Minoxidil are mentioned as having clinical evidence for increasing hair counts, but with potential side effects.
Hair growth relies on mechanical forces, not just chemicals, with tissue acting like a motor. Minoxidil and finasteride help, but maintaining tissue elasticity and addressing mechanical issues are essential.
Whether using both Fluridil and Alfatradiol together could be more effective than either one alone as a hair loss treatment, given their different mechanisms of action.
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
The user shared 8 months of hair loss progress using dutasteride, oral minoxidil, RU58841 mixed with liquid minoxidil, and foam minoxidil. They started all treatments simultaneously, using RU58841 for its different mechanism of action.
Evidence-based treatments for androgenic alopecia, such as minoxidil, finasteride, low-level laser light therapy, dutasteride, platelet-rich plasma, and topical ketoconazole. It discusses the efficacy, safety, and mechanism of action of these treatments, as well as future developments in understanding this polygenic condition.
DHT may inhibit hair growth by affecting mitochondrial function, leading to hair follicle miniaturization. Treatments like minoxidil and PP405 may promote hair growth by altering metabolic pathways, potentially counteracting DHT's effects.
PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.
Hair loss may be linked to the GPR133 receptor, independent of the androgen receptor pathway. Treatments like finasteride, dutasteride, minoxidil, RU58841, and KX-826 show varying results, with hair loss persisting due to high testosterone and GPR133's role.
Hair loss matters, but focusing on self-improvement like working out, using treatments like minoxidil and finasteride, and building confidence can help. People often suggest extreme solutions like becoming a millionaire or bodybuilder, but practical steps are more beneficial.
Minoxidil and finasteride work through different mechanisms; minoxidil-dependent hair requires continued use to maintain growth, while finasteride prevents further hair loss but cannot sustain minoxidil gains alone. Current treatments like minoxidil, finasteride, and others need indefinite use, as no permanent solution exists yet.
Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.
The mechanism of Androgenic Alopecia and practical applications of treatments like Minoxidil, Finasteride, RU58841, dermarolling, scalp massages, anti-fungals, progesterone, estrogen, PPAR-γ activators, reducing oxidative stress, and scalp exercises. It explains why DHT is important in AA and how other factors might be involved such as hypoxia, increased DKK-1 expression, morphological changes to the scalp, skull growth during childhood/puberty, and blood flow.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
Topical finasteride is currently more effective than pyrilutamide for hair loss. Combining treatments like topical finasteride and pyrilutamide may enhance results due to different mechanisms.
Using both finasteride and spironolactone together is more effective for hair loss in females, as they have different mechanisms and complement each other. It's important to avoid these medications during pregnancy and choose birth control with anti-androgenic activity.
Microneedling the scalp can cause sneezing, runny nose, and watery eyes due to nerve stimulation, histamine release, reflex actions, or sinus relief. Several users experience similar symptoms.
The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.
Minoxidil's effects on hair regrowth diminish over time because it doesn't address the root cause of hair loss, and its mechanism isn't fully understood. Combining it with treatments like finasteride or dutasteride can help maintain its effectiveness, but permanent solutions are unlikely due to the complexity of hair loss biology.
The conversation discusses GT20029, a drug in Phase II trials that targets androgen receptors with minimal systemic effects, and TDM-105795, a growth stimulant with a different mechanism than minoxidil that may revive papilla stem cells. Both are potential new treatments for hair loss.
Pyrilutamide is believed to be more effective than RU58841 and 1 mg finasteride in treating hair loss, with no systemic hormonal effects and the potential to block more than 31% of scalp DHT. It may also antagonize scalp testosterone due to its action as an androgen receptor antagonist.
The post discusses the difference in effects of Minoxidil (Min) on scalp and facial hair. The user questions why Min-induced hair growth on the scalp is temporary, while facial hair growth seems permanent, even after stopping Min. They propose theories, including different Min mechanisms on body and facial hair, the role of DHT, and the possibility of not achieving fully terminal hair. The responses include personal experiences and theories about Min's effects on hair growth.
Finasteride prevents further hair loss by blocking DHT, while minoxidil stimulates hair growth by prolonging the active phase of hair follicles. Stopping minoxidil can lead to loss of regrown hair because finasteride does not address the same growth mechanism.
Saw palmetto's fatty acids, particularly lauric and linoleic acids, inhibit enzymes linked to hair loss, while sterols like beta-sitosterol are less effective due to poor absorption. The conversation questions which specific compounds in saw palmetto contribute to its anti-androgenic effects.
PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.
Microneedling and tretinoin may enhance minoxidil absorption for hair loss, but evidence on their effectiveness is limited. Iron supplements and broccoli sprouts are suggested for enzyme activation, but their impact on hair is unclear.